Lowering LDL Cholesterol by 62% Recently Achieved Through Clinical Trial

A clinical trial for a one-time gene-editing treatment has reduced LDL cholesterol levels by 62%, according to reporting from Men’s Health on June 7, 2026. The therapy utilizes CRISPR-based technology to permanently disable a specific gene in the liver, potentially offering a permanent alternative to daily cholesterol-lowering medications.

The treatment targets the PCSK9 gene, which plays a critical role in how the body regulates low-density lipoprotein (LDL), often called bad cholesterol. By using gene editing to “turn off” this gene, the liver can more effectively remove LDL from the bloodstream, reducing the risk of plaque buildup in the arteries.

This approach differs from traditional therapies because it modifies the patient’s DNA. While standard treatments manage cholesterol levels through ongoing chemical intervention, this technology seeks to fix the underlying genetic mechanism permanently.

High LDL levels are a primary driver of atherosclerosis, a condition where fatty deposits narrow the arteries. This narrowing restricts blood flow and can lead to heart attacks or strokes if a plaque ruptures and forms a clot.

The 62% reduction in LDL reported on June 7, 2026, suggests a significant shift in how clinicians might treat familial hypercholesterolemia or severe cardiovascular risk. Patients with genetic predispositions to high cholesterol often struggle to reach target LDL levels even with maximum doses of traditional drugs.

Traditional statins work by inhibiting the enzyme HMG-CoA reductase in the liver to slow down the production of cholesterol. However, statins require daily adherence and can cause side effects such as muscle pain in some patients.

Another class of drugs, PCSK9 inhibitors, uses monoclonal antibodies to block the PCSK9 protein. While highly effective, these require regular injections, often every two to four weeks, and involve significant ongoing costs.

The CRISPR-based method removes the need for repeated dosing. By editing the DNA sequence of the PCSK9 gene, the body stops producing the protein entirely, effectively mimicking a natural genetic mutation found in some people who have lifelong low LDL levels and a very low risk of heart disease.

The technology employed is often a refined version of CRISPR-Cas9 known as base editing. Unlike traditional CRISPR, which cuts both strands of the DNA helix, base editing can change a single “letter” of the genetic code without creating a double-strand break. This precision is intended to reduce the risk of unintended mutations elsewhere in the genome.

Despite the 62% reduction in LDL, the permanent nature of gene editing introduces specific medical considerations that differ from reversible drug treatments.

If a patient experiences an adverse reaction to a statin, they can simply stop taking the pill. With a one-time gene edit, the change to the liver’s DNA is irreversible. This makes the initial safety profile and the accuracy of the edit paramount.

Researchers must also monitor for “off-target effects,” where the CRISPR mechanism might accidentally edit a similar DNA sequence in a different gene. Such errors could potentially lead to cellular dysfunction or other long-term health complications.

The long-term durability of the 62% reduction also remains a point of study. Because liver cells regenerate, scientists are tracking whether the edited cells persist over several years or if the cholesterol-lowering effect diminishes as new, unedited cells replace the old ones.

The transition from chronic management to a one-time cure could fundamentally change the economics of heart health. While the upfront cost of a gene-editing procedure is likely to be high, it may offset the decades of expense associated with daily medication and the treatment of acute cardiovascular events.

The current focus for this technology remains in clinical trial phases, prioritizing patients with the highest risk factors. Further data will be required to determine if this treatment is safe and effective for the general population with mild to moderate high cholesterol.